Stability of HER2-positive status in breast carcinoma: A comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment

Annals of Oncology

Volumn 22, Issue 7, 2011, Pages 1547-1553

  Xiao, C ^a,b   Gong, Y ^a   Han, E Y ^a   Gonzalez Angulo, A M ^a   Sneige, N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Breast; Carcinoma; HER2; Metastatic; Primary; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RELAPSE; CONTROLLED STUDY; DISTANT METASTASIS; GENETIC ANALYSIS; GENETIC STABILITY; HUMAN; LOCOREGIONAL METASTASIS; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; PRIMARY TUMOR; PRIORITY JOURNAL; REGIONAL METASTASIS; SCORING SYSTEM; TREATMENT RESPONSE;

EID: 79959693453     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq623     Document Type: Article

References (36)

1. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-2648.
2. Dawood S, Broglio K, Buzdar AU et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 010; 28: 92-98.
3. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 001; 344: 783-792.
4. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin ncol 2002; 20: 719-726.
5. Gancberg D, Di Leo A, Cardoso F et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002; 13: 1036-043.
6. Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 2005; 103: 763-1769.
7. Masood S, Bui MM. Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 2000; 30: 59-265.
8. Simon R, Nocito A, Hubscher T et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001; 93: 1141-1146.
9. Vincent-Salomon A, Jouve M, Genin P et al. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the etastatic process. Cancer 2002; 94: 2169-2173.
10. Lorincz T, Toth J, Badalian G et al. HER-2/neu genotype of breast cancer may change in bone metastasis. Pathol Oncol Res 2006; 12: 149-152.
11. Pectasides D, Gaglia A, Arapantoni-Dadioti P et al. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated ith trastuzumab-based therapy. Anticancer Res 2006; 26: 647-653.
12. Lower EE, Glass E, Blau R, Harman S. HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 2009; 113: 301-306.
13. Ropero S, Menendez JA, Vazquez-Martin A et al. Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma. Breast Cancer Res Treat 2004; 6: 125-137.
14. Fornier MN, Seidman AD, Schwartz MK et al. Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 2005; 16: 234-239.
15. Mazouni C, Hall A, Broglio K et al. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer 007; 109: 496-501.
16. Lennon S, Barton C, Banken L et al. Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic reast cancer. J Clin Oncol 2009; 27: 1685-1693.
17. Burstein HJ, Harris LN, Gelman R et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003; 21: 46-53.
18. Harris LN, You F, Schnitt SJ et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007; 13: 1198-207.
19. Hurley J, Doliny P, Reis I et al. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast ancer. J Clin Oncol 2006; 24: 1831-1838.
20. Mittendorf EA, Wu Y, Scaltriti M et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res 2009; 15: 381-7388.
21. Kunitomo K, Inoue S, Ichihara F et al. A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel. Hum Pathol 2004; 35: 379-381.
22. Dawood S, Resetkova E, Gonzalez-Angulo AM. Trastuzumab administration associated with change in HER2 status. Clin Breast Cancer 2008; 8: 366-369.
23. Konecny G, Pauletti G, Pegram M et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl ancer Inst 2003; 95: 142-153.
24. Munzone E, Curigliano G, Rocca A et al. Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus hemotherapy. Breast Cancer Res 2006; 8: R4.
25. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
26. Gong Y, Symmans WF, Krishnamurthy S et al. Optimal fixation conditions for immunocytochemical analysis of estrogen receptor in cytologic specimens of breast carcinoma. Cancer 2004; 102: 34-40.
27. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
28. Regitnig P, Schippinger W, Lindbauer M et al. Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J Pathol 2004; 203: 918-926.
29. Santinelli A, Pisa E, Stramazzotti D, Fabris G. HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 2008; 122: 99-1004.
30. Edgerton SM, Moore D II, Merkel D, Thor AD. erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol 2003; 11: 214-221.
31. Pertschuk LP, Axiotis CA, Feldman JG et al. Marked intratumoral heterogeneity of the proto-oncogene Her-2/neu determined by three different detection systems. Breast J 1999;: 369-374.
32. Kuukasjarvi T, Karhu R, Tanner M et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 997; 57: 1597-1604.
33. Gong Y, Yan K, Lin F et al. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 2007; 8: 203-11.
34. Roche PC, Suman VJ, Jenkins RB et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002; 94: 855-57.
35. Tubbs RR, Pettay JD, Roche PC et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical falsepositives do not get the message. J Clin Oncol 2001; 19: 2714-2721.
36. Sabnis G, Schayowitz A, Goloubeva O et al. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res 2009; 69: 1416-428.